{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:57Z","timestamp":1784977257984,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04257-0","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:19:37Z","timestamp":1771251577000},"page":"3345-3365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Shuangyan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XianYu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-1328","authenticated-orcid":false,"given":"Le","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4257_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465\u201372.","journal-title":"JAMA Oncol"},{"key":"4257_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4257_CR3","doi-asserted-by":"publisher","first-page":"1814-.e1","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD Jr. Advances in cancer immunotherapies. Cell. 2023;186:1814-.e1.","journal-title":"Cell"},{"key":"4257_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060795","author":"Y Moon","year":"2024","unstructured":"Moon Y, Cho H, Kim K. Nano-delivery of immunogenic cell death inducers and immune checkpoint blockade agents: single-nanostructure strategies for enhancing immunotherapy. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16060795.","journal-title":"Pharmaceutics"},{"key":"4257_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100268","author":"J Sun","year":"2021","unstructured":"Sun J, Chen Y, Lubben B, Adebayo O, Muz B, Azab AK. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leuk Res Rep. 2021. https:\/\/doi.org\/10.1016\/j.lrr.2021.100268.","journal-title":"Leuk Res Rep"},{"key":"4257_CR6","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.2174\/1381612828666221006123144","volume":"28","author":"L Gao","year":"2022","unstructured":"Gao L, He Z, Wu Y. Advances in anti-metabolic disease treatments targeting CD47. Curr Pharm Des. 2022;28:3720\u20138.","journal-title":"Curr Pharm Des"},{"key":"4257_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.18632\/oncotarget.28607","volume":"15","author":"M Gracia-Hernandez","year":"2024","unstructured":"Gracia-Hernandez M, Suresh M, Villagra A. The advances in targeting CD47\/SIRP\u03b1 \u201cdo not eat me\u201d axis and their ongoing challenges as an anticancer therapy. Oncotarget. 2024;15:462\u20135.","journal-title":"Oncotarget"},{"key":"4257_CR8","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c02926","author":"YJ Ma","year":"2024","unstructured":"Ma YJ, Shi L, Qin YT, He XW, Li WY, Zhang YK. Dual template molecularly imprinted polymers targeting blockade of CD47 for enhanced macrophage phagocytosis and synergistic antimetabolic therapy. ACS Appl Mater Interfaces. 2024. https:\/\/doi.org\/10.1021\/acsami.4c02926.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4257_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100862","author":"C-Y Huang","year":"2020","unstructured":"Huang C-Y, Ye Z-H, Huang M-Y, Lu J-J. Regulation of CD47 expression in cancer cells. Transl Oncol. 2020. https:\/\/doi.org\/10.1016\/j.tranon.2020.100862.","journal-title":"Transl Oncol"},{"key":"4257_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.32604\/or.2023.042383","volume":"32","author":"Q Chen","year":"2024","unstructured":"Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2024;32:49\u201360.","journal-title":"Oncol Res"},{"key":"4257_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature. 2024;630:457\u201365.","journal-title":"Nature"},{"key":"4257_CR12","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-11-2303","volume":"72","author":"S Ning","year":"2012","unstructured":"Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012;72:2600\u20138.","journal-title":"Cancer Res"},{"key":"4257_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2020.05.009","volume":"47","author":"B Oronsky","year":"2020","unstructured":"Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ. Just eat it: a review of CD47 and SIRP-\u03b1 antagonism. Semin Oncol. 2020;47:117\u201324.","journal-title":"Semin Oncol"},{"key":"4257_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(15)00089-3","volume":"16","author":"T Reid","year":"2015","unstructured":"Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1133\u201342.","journal-title":"Lancet Oncol"},{"key":"4257_CR15","first-page":"705","volume":"32","author":"W Luo","year":"2020","unstructured":"Luo W, Tao J, Zheng L, Zhang T. Current epidemiology of pancreatic cancer: challenges and opportunities. Chinese J Cancer Res Zhongguo Zhong Liu Yan Jiu. 2020;32:705\u201319.","journal-title":"Chinese J Cancer Res Zhongguo Zhong Liu Yan Jiu"},{"key":"4257_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10615-w","volume":"23","author":"Y Nie","year":"2023","unstructured":"Nie Y, Liu C, Liu Q, Zhu X. CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling. BMC Cancer. 2023;23:150.","journal-title":"BMC Cancer"},{"key":"4257_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1042\/BCJ20230374","volume":"481","author":"KC LaRue-Nolan","year":"2024","unstructured":"LaRue-Nolan KC, Raja Arul GL, Sigafoos AN, Shi J, Fernandez-Zapico ME. Insights into the mechanisms driven by H3K4 KMTs in pancreatic cancer. Biochem J. 2024;481:983\u201397.","journal-title":"Biochem J"},{"key":"4257_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.omtn.2021.12.036","volume":"27","author":"H Qian","year":"2022","unstructured":"Qian H, Zhou T, Fu Y, Guo M, Yang W, Zhang D, et al. Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity. Mol Ther Nucleic Acids. 2022;27:763\u201373.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4257_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03118-w","author":"Y Song","year":"2024","unstructured":"Song Y, Zhang Y, Wang Z, Lin Y, Cao X, Han X, et al. CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway. Oncogene. 2024. https:\/\/doi.org\/10.1038\/s41388-024-03118-w.","journal-title":"Oncogene"},{"key":"4257_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396719","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Z, Yuan J, Yu J, Chen D. Spatial interaction and functional status of CD68(+)SHP2(+) macrophages in tumor microenvironment correlate with overall survival of NSCLC. Front Immunol. 2024;15:1396719.","journal-title":"Front Immunol"},{"key":"4257_CR21","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","volume":"1","author":"W Shen","year":"2022","unstructured":"Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1:e36.","journal-title":"iMeta"},{"key":"4257_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400-16.e11.","journal-title":"Cell"},{"key":"4257_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"4257_CR24","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"C-J Liu","year":"2018","unstructured":"Liu C-J, Hu F-F, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34:3771\u20132.","journal-title":"Bioinformatics"},{"key":"4257_CR25","doi-asserted-by":"crossref","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. <GSVA gene set variation analysis for microarray and RNA-seq data.pdf>. 2013.","DOI":"10.1186\/1471-2105-14-7"},{"key":"4257_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0655-5","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019. https:\/\/doi.org\/10.1186\/s13073-019-0655-5.","journal-title":"Genome Med"},{"key":"4257_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016. https:\/\/doi.org\/10.1186\/s13059-016-1070-5.","journal-title":"Genome Biol"},{"key":"4257_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017. https:\/\/doi.org\/10.1186\/s13059-017-1349-1.","journal-title":"Genome Biol"},{"key":"4257_CR29","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023;51:D1425\u201331.","journal-title":"Nucleic Acids Res"},{"key":"4257_CR30","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res"},{"key":"4257_CR31","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"XS Liu","year":"2020","unstructured":"Liu XS, Li B, Chen Q, Li J, Cohen D, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"4257_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunity. 2018;48:812-30.e14.","journal-title":"Immunity"},{"key":"4257_CR33","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","volume":"11","author":"J Hu","year":"2021","unstructured":"Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11:3089\u2013108.","journal-title":"Theranostics"},{"key":"4257_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"key":"4257_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173:338-54.e15.","journal-title":"Cell"},{"key":"4257_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899\u2013905.","journal-title":"Nature"},{"key":"4257_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00073.","journal-title":"JCO Precis Oncol"},{"key":"4257_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac558","author":"CJ Liu","year":"2023","unstructured":"Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y, et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2023. https:\/\/doi.org\/10.1093\/bib\/bbac558.","journal-title":"Brief Bioinform"},{"key":"4257_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098441","author":"S-Y Koo","year":"2023","unstructured":"Koo S-Y, Park E-J, Noh H-J, Jo S-M, Ko B-K, Shin H-J, et al. Ubiquitination links DNA damage and repair signaling to cancer metabolism. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24098441.","journal-title":"Int J Mol Sci"},{"key":"4257_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15:459\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"4257_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02041-8","author":"Y Li","year":"2024","unstructured":"Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024. https:\/\/doi.org\/10.1186\/s12943-024-02041-8.","journal-title":"Mol Cancer"},{"key":"4257_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"J-J Loh","year":"2024","unstructured":"Loh J-J, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31:617\u201339.","journal-title":"Cell Stem Cell"},{"key":"4257_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/gcc.22939","volume":"60","author":"D Gonzalez","year":"2021","unstructured":"Gonzalez D, Stenzinger A. Homologous recombination repair deficiency (HRD): from biology to clinical exploitation. Genes Chromosomes Cancer. 2021;60:299\u2013302.","journal-title":"Genes Chromosomes Cancer"},{"key":"4257_CR44","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"4257_CR45","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024;629:443\u20139.","journal-title":"Nature"},{"key":"4257_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00776-9","author":"W Lin","year":"2020","unstructured":"Lin W, Noel P, Borazanci EH, Lee J, Amini A, Han IW, et al. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med. 2020. https:\/\/doi.org\/10.1186\/s13073-020-00776-9.","journal-title":"Genome Med"},{"key":"4257_CR47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun B-F, Chen C-Y, Zhou J-Y, Chen Y-S, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29:725\u201338.","journal-title":"Cell Res"},{"key":"4257_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.943","volume":"12","author":"R Bouwstra","year":"2022","unstructured":"Bouwstra R, van Meerten T, Bremer E. CD47-SIRP\u03b1 blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12:e943.","journal-title":"Clin Transl Med"},{"key":"4257_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155076","volume":"11","author":"P Ke","year":"2016","unstructured":"Ke P, Shao BZ, Xu ZQ, Wei W, Han BZ, Chen XW, et al. Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages. PLoS ONE. 2016;11:e0155076.","journal-title":"PLoS ONE"},{"key":"4257_CR50","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/s41590-024-01945-3","volume":"25","author":"Y Cai","year":"2024","unstructured":"Cai Y, Lu Z, Chen C, Zhu Y, Chen Z, Wu Z, et al. An atlas of genetic effects on cellular composition of the tumor microenvironment. Nat Immunol. 2024;25:1959\u201375.","journal-title":"Nat Immunol"},{"key":"4257_CR51","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.cell.2022.02.015","volume":"185","author":"M Dhainaut","year":"2022","unstructured":"Dhainaut M, Rose SA, Akturk G, Wroblewska A, Nielsen SR, Park ES, et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022;185:1223-39.e20.","journal-title":"Cell"},{"key":"4257_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206380","author":"L Du","year":"2023","unstructured":"Du L, Su Z, Wang S, Meng Y, Xiao F, Xu D, et al. EGFR\u2010induced and c\u2010Src\u2010mediated CD47 phosphorylation inhibits TRIM21\u2010dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion. Adv Sci. 2023. https:\/\/doi.org\/10.1002\/advs.202206380.","journal-title":"Adv Sci"},{"key":"4257_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0770-1","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0770-1.","journal-title":"J Hematol Oncol"},{"key":"4257_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"4257_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0479-7","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018. https:\/\/doi.org\/10.1186\/s40425-018-0479-7.","journal-title":"J Immunother Cancer"},{"key":"4257_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01525","author":"Y Liu","year":"2020","unstructured":"Liu Y, Chang Y, He X, Cai Y, Jiang H, Jia R, et al. CD47 enhances cell viability and migration ability but inhibits apoptosis in endometrial carcinoma cells via the PI3K\/Akt\/mTOR signaling pathway. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01525.","journal-title":"Front Oncol"},{"key":"4257_CR57","first-page":"415","volume":"27","author":"X Liu","year":"2019","unstructured":"Liu X, Wu X, Wang Y, Li Y, Chen X, Yang W, et al. CD47 promotes human glioblastoma invasion through activation of the PI3K\/Akt pathway. Oncol Res Featur Preclin Clin Cancer Ther. 2019;27:415\u201322.","journal-title":"Oncol Res Featur Preclin Clin Cancer Ther"},{"key":"4257_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50136-z","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wang W, Xu H, Liang Y, Ding J, Lv M, et al. Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRP\u03b1 blockade efficacy. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-50136-z.","journal-title":"Nat Commun"},{"key":"4257_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162870","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou H, Liu P, Lv D, Shi Y, Tang B, et al. SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47\/SIRP\u03b1 axis. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI162870.","journal-title":"J Clin Invest"},{"key":"4257_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2408088","volume":"20","author":"L Qin","year":"2024","unstructured":"Qin L, Li Y, Zeng R, He Y, Chen X, Xiao L, et al. A novel anti-CD47 antibody with therapeutic potential for NK\/T-cell lymphoma. Hum Vaccin Immunother. 2024;20:2408088.","journal-title":"Hum Vaccin Immunother"},{"key":"4257_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1572764","volume":"16","author":"M Xiao","year":"2025","unstructured":"Xiao M, Li X. The impact of the tumor microenvironment on macrophages. Front Immunol. 2025;16:1572764.","journal-title":"Front Immunol"},{"key":"4257_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1746172","author":"B Oronsky","year":"2020","unstructured":"Oronsky B, Carter CA, Caroen S, Scribner C, Oronsky A, Reid TR. RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an \u201cerythrophagoimmunotherapeutic.\u201d Oncoimmunology. 2020. https:\/\/doi.org\/10.1080\/2162402X.2020.1746172.","journal-title":"Oncoimmunology"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04257-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:10Z","timestamp":1784975350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04257-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4257"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04257-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. This study was performed in line with the principles of the Declaration of Helsinki. The research plan was approved by the Ethics Committee of the First Affiliated Hospital of Dali University on September 27, 2024 (Project Number: DFY20240927001).","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}